RHHBYRoche Holdings AG ADR
RHHBY
Roche Holdings AG ADR3,607
Mkt Cap
$283.41BVolume
1.36M52W High
$53.0052W Low
$34.75PE Ratio
29.98RHHBY Fundamentals
Price
$51.37Prev Close
$51.45Open
$51.2950D MA
$47.19Beta
0.32Avg. Volume
2.45MEPS (Annual)
$1.47P/B
9.08Rev/Employee
$665,306.28Throwing Precision Darts: The Company Leading Next Evolution of Cancer Radiation
Radiation therapy has been a foundation of cancer care for more than a century. From early X-ray machines to today’s image-guided systems, the goal has remained the same: deliver enough energy to destroy tumors while sparing healthy tissue. What has changed, gradually, then suddenly, is the level of precision clinicians can bring to that task. A new generation of technologies is pushing radiation beyond its historical limits, opening therapeutic possibilities for patients who previously had few or no options. Alpha Tau Medical Ltd. (Nasdaq: DRTS) sits at the center of that ...
AllPennyStocks·18h ago
Corcept Tanks on FDA's CRL to Relacorilant NDA in Hypercortisolism
CORT's shares plunge after the FDA issues a CRL to relacorilant's new drug application for treating patients with hypercortisolism.
Zacks·4d ago
REGN Soars 41% in Six Months: Is There More Upside Potential in 2026?
Regeneron shares are up 41% in six months as FDA approvals, strong Dupixent profits and oncology gains lift investor confidence.
Zacks·4d ago
When Wall Street Rotates, Biotech Innovators Emerge: The Untapped Opportunities in Oncology
Market rotations are as old as Wall Street itself. When capital exits overheated sectors like big tech, it often finds its way into undervalued industries ripe for rediscovery. The latest shift, away from pricey artificial intelligence and semiconductor stocks, has once again turned investors’ attention toward biotechnology. And within biotech, the most compelling breakthroughs are not in computing or automation, but in humanity’s longest-standing battle: defeating cancer.As institutional money seeks new opportunities, healthcare and biotech have emerged as natural ...
AllPennyStocks·15d ago
When Wall Street Rotates, Biotech Innovators Emerge: The Untapped Opportunities in Oncology
Market rotations are as old as Wall Street itself. When capital exits overheated sectors like big tech, it often finds its way into undervalued industries ripe for rediscovery. The latest shift, away from pricey artificial intelligence and semiconductor stocks, has once again turned investors’ attention toward biotechnology. And within biotech, the most compelling breakthroughs are not in computing or automation, but in humanity’s longest-standing battle: defeating cancer.As institutional money seeks new opportunities, healthcare and biotech have emerged as natural ...
AllPennyStocks·15d ago
When Wall Street Rotates, Biotech Innovators Emerge: The Untapped Opportunities in Oncology
Market rotations are as old as Wall Street itself. When capital exits overheated sectors like big tech, it often finds its way into undervalued industries ripe for rediscovery. The latest shift, away from pricey artificial intelligence and semiconductor stocks, has once again turned investors’ attention toward biotechnology. And within biotech, the most compelling breakthroughs are not in computing or automation, but in humanity’s longest-standing battle: defeating cancer.As institutional money seeks new opportunities, healthcare and biotech have emerged as natural ...
AllPennyStocks·15d ago
Can Merck Successfully Steer Through the Upcoming Headwinds?
MRK faces looming Keytruda LOE, falling Gardasil sales and pricing pressure, but new products, pipeline and planned cost savings aim to offset the headwinds.
Zacks·18d ago
PCSA Stock Soars on Upbeat Clinical Update From Breast Cancer Study
Processa Pharmaceuticals stock jumps 122% after a phase II update shows NGC-Cap delivers higher active metabolite exposure with comparable safety in breast cancer.
Zacks·19d ago
<
1
2
...
>